Dalcetrapib treatment increased HDL-C and apolipoprotein A@ by @ and @ % , respectively ( both P < @ ) and total cholesterol efflux by @ % ( P = @ ) after @ weeks , principally via an increase in non-ATP-binding cassette transporter ( ABC ) A@-mediated efflux , without statistically significant changes in pre-@-HDL levels .